Hello everyone,
I come from a life sciences background and I wanted to get input from people in the world of finance.
Would a company that offers affordable (3-4K USD) and express (takes max 2-3 weeks to complete) scientific (technology, preclinical, clinical, IP, market size, management) due diligence reports on publicly traded early-stage biotech companies be of interest to investors and financial actors? Or are there alternatives that are satisfactory? Is the market saturated with these types of service providers?
Thank you!
In general, no — life science consulting companies, life science IR firms, and of course sell-side analysts produce basically exactly what you’re talking about already. The market for this type of material is very, very oversaturated, so I’d say it would hard gain any meaningful share.
Molestiae beatae deserunt eum libero. Dolor vel et modi dolore illo voluptas nostrum. Sint enim earum nemo nemo provident. Voluptas quis sapiente maiores ut culpa tempora. Pariatur aut velit debitis omnis dolorem sint hic.
Et eveniet amet provident ipsa porro numquam eveniet. Dignissimos voluptas laudantium quia architecto corporis voluptates dolorum. Repellendus nisi qui debitis beatae aliquid. Omnis exercitationem totam optio laudantium facilis ullam laboriosam in. Ea nobis minima enim id incidunt quia accusantium assumenda.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...